Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Belgium / NCT06966128
Starting soon Not applicable

Transcranial Electrical Stimulation in Multiple Sclerosis

NCT06966128 · tracked via the Priya Life Science Belgium tracker
Sponsor
Universitair Ziekenhuis Brussel
Phase
Not applicable
Started
2025-06-01
Last updated
2025-05-29

Condition(s) studied

Multiple Sclerosis

Investigational drug(s) / intervention(s)

transcranial Direct Current Stimulation

transcranial Direct Current Stimulation: Stimulation intensity: Variable (between 1 mA and 2 mA), Electrode placement: Dorsolateral prefrontal cortex, Duration: 10 minutes

Study summary

First the investigators will examine if the blood flow in the brain is different in patients with Multiple Sclerosis compared to healthy volunteers.

HOW?

\- The blood flow of the subjects is imaged by use of a special MRI-technique.

Secondly, the investigators will examine if the blood flow can determine disease progression.

HOW? - Multiple Sclerosis patients are asked for a follow-up visit after two years.

The main goal is to understand the effect of transcranial Direct Current Stimulation (tDCS) on the cerebral blood flow.

* Does tDCS result in a different blood flow, in which brain regions?
* Is there a difference between healthy volunteers and Multiple Sclerosis patients?

HOW?

\- Participants get two session of tDCS. Before, during and after stimulation MRI scans are performed.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion criteria - MS patient * EDSS ≥ 2 and EDSS ≤ 6.5 * Age ≥ 18 Exclusion criteria - MS patient * EDSS \> 6.5 * Incompatibility with MRI * Relapse within three months before the study and its use of corticosteroids * Disabling concomitant neuropsychiatric diseases * Chance of pregnancy, breastfeeding * Contraindications to tDCS Inclusion criteria - Healthy Volunteer • Age ≥ 18 Exclusion criteria - Healthy Volunteer * Incompatibility with MRI * Disabling concomitant neuropsychiatric diseases * Chance of pregnancy, breastfeeding * Contraindications to tDCS

Primary outcome measure(s)

  • Cerebral blood flow (CBF) — Visit 1 (baseline), visit 2 (+-1 week after visit 1), visit 3 (2 years after visit 1)
    Measure of brain perfusion. CBF is measured at baseline and after two years. Additionally, the investigators will measure CBF before-, during-, and after tDCS.

Trial sites (2)

FacilityCityRegionStatus
University hospital of Brussels Brussels Belgium
National MS Center Melsbroek Melsbroek Belgium

More Universitair Ziekenhuis Brussel trials in Belgium

The Value of Spleen Stiffness Measurement in Patients With PBC Starting soon
Bio-electrical Impedance Analysis in Patients With Functional Dyspepsia Recruiting
Between the Belly and the Brain: Distorted Gut-brain Crosstalk in Early-life Adversity Starting soon
Multicenter Registry of Atrial Fibrillation Ablation With Radiofrequency Balloon Catheter Recruiting
Live Birth Rate After Sperm Selection Using ZyMōt Multi (850µL) Device for Intra Uterine Insemination Recruiting

Other trials for the same condition

Eccentric Cycling in Multiple Sclerosis Rehabilitation Active, not recruiting
A Specialized Diet for Multiple Sclerosis Recruiting
A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis Active, not recruiting
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS) Active, not recruiting
At Home Use of Stimulation Suits for Managing MS Symptoms Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06966128 on ClinicalTrials.gov ↗ ← All trials in Belgium